BUZZ-Grail rises after TD Cowen upgrade

Reuters03-18
BUZZ-Grail rises after TD Cowen upgrade

** Shares of diagnostics firm Grail GRAL.O rise 4.2% to $49.36 premarket

** Brokerage TD Cowen upgrades GRAIL to “buy” from “hold”, but cuts its price target to $65 from $114

** TD Cowen says the recent sell-off after the NHS Galleri trial miss has created an attractive entry point, despite the study missing its main goal

** Brokerage says its expert checks remain positive on GRAIL’s blood test that aims to detect multiple cancers early, with a meaningful drop in late-stage cancers

** TD Cowen estimates a roughly 75% chance of U.S. approval for the test and around a 50% chance of Medicare coverage

** GRAIL shares had fallen about 60% since mid-February before the upgrade, brokerage says

** Shares rose nearly four fold in 2025

(Reporting by Sahil Pandey in Bengaluru)

((Sahil.Pandey@thomsonreuters.com))

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment